Drug Sponsors

Forest Labs and Nabriva to develop novel antibacterial agent

Friday, June 1, 2012 10:43 AM

Forest Laboratories, an international pharmaceutical manufacturer and marketer, and biotech Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781.

More... »

Marina Biotech lays off 90% of staff

Friday, June 1, 2012 10:20 AM

Marina Biotech, a nucleic acid-based drug discovery and development company based in Bothell, Wash., announced that it does not currently have adequate funding to continue implementing its business plan.

More... »

Stiefel to acquire psoriasis topical agent from Welichem Biotech

Thursday, May 31, 2012 02:24 PM

Stiefel, a subsidiary of GlaxoSmithKline, has signed an agreement with Canada-based Welichem Biotech to acquire exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.

More... »

UCB expands in Brazil

Thursday, May 31, 2012 11:51 AM

UCB, a global biopharmaceutical company focused on severe diseases, has signed an agreement to acquire 51% of Meizler Biopharma, a privately-owned Brazilian pharmaceutical company.

More... »

Bayer and Covance form strategic partnership

Thursday, May 31, 2012 10:52 AM

Bayer HealthCare and Covance, a CRO based in Princeton, N.J., have established a long-term strategic partnership in the area of clinical drug development including R&D services related to phase II-IV clinical studies and central laboratory services.

More... »

GSK and HKCF establish Cancer Drug Relief Fund in Hong Kong

Wednesday, May 30, 2012 02:48 PM

In a joint effort, GlaxoSmithKline and Hong Kong Cancer Fund have established the Cancer Drug Relief Fund, a $5.4 million three-year pilot project dedicated to offering financial assistance by way of subsidized cancer drugs to low income patients and those in the “sandwich class.”

More... »

Vertex corrects, provides additional data on cystic fibrosis study

Wednesday, May 30, 2012 10:44 AM

Vertex Pharmaceuticals of Cambridge, Mass., has released a correction to the previously reported responder analysis, as well as additional data from, its recent interim analysis of an ongoing phase II combination study of VX-809 and Kalydeco (ivacaftor) that showed significant improvements in lung function (forced expiratory volume in one second, FEV1) among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

More... »

Biopharmas that attract corporate venture investment more likely to be acquired, go public, analysis finds

Wednesday, May 30, 2012 10:42 AM

Therapeutics companies that attract investment from corporate venture arms are more likely than other venture-backed companies to enter licensing deals, be acquired or complete an initial public offering, according to analysis from Burrill & Company, a diversified global financial services firm focused on the life sciences industry.

More... »

Teralys Capital, Lilly invest in new $150 million fund for life sciences

Wednesday, May 30, 2012 10:36 AM

Teralys Capital has invested $65 million, along with other amounts from Eli Lilly and other partners, in TVM Life Science Ventures VII, which closed on an initial size of $150 million.

More... »

Takeda to acquire Multilab in Brazil

Wednesday, May 30, 2012 10:31 AM

Takeda Farmacêutica Brasil, a wholly-owned subsidiary of Takeda Pharmaceutical, has agreed to acquire Multilab Industria e Comercio de Produtos Farmaceuticos of Sao Paulo, Brazil.

More... »